Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

February 12, 2013; 80 (7) Article

A randomized controlled trial of intranasal ketamine in migraine with prolonged aura

Shazia K. Afridi, Nicola J. Giffin, Holger Kaube, Peter J. Goadsby
First published January 30, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182824e66
Shazia K. Afridi
From the Headache Group, Department of Neurology, University of California, San Francisco. S.K.A. is currently affiliated with the Department of Neurology, Guy's Hospital, London, UK. N.J.G. is currently affiliated with the Department of Neurology, Royal United Hospital, Bath, UK. H.K. is currently located in Munich, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola J. Giffin
From the Headache Group, Department of Neurology, University of California, San Francisco. S.K.A. is currently affiliated with the Department of Neurology, Guy's Hospital, London, UK. N.J.G. is currently affiliated with the Department of Neurology, Royal United Hospital, Bath, UK. H.K. is currently located in Munich, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holger Kaube
From the Headache Group, Department of Neurology, University of California, San Francisco. S.K.A. is currently affiliated with the Department of Neurology, Guy's Hospital, London, UK. N.J.G. is currently affiliated with the Department of Neurology, Royal United Hospital, Bath, UK. H.K. is currently located in Munich, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Goadsby
From the Headache Group, Department of Neurology, University of California, San Francisco. S.K.A. is currently affiliated with the Department of Neurology, Guy's Hospital, London, UK. N.J.G. is currently affiliated with the Department of Neurology, Royal United Hospital, Bath, UK. H.K. is currently located in Munich, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
A randomized controlled trial of intranasal ketamine in migraine with prolonged aura
Shazia K. Afridi, Nicola J. Giffin, Holger Kaube, Peter J. Goadsby
Neurology Feb 2013, 80 (7) 642-647; DOI: 10.1212/WNL.0b013e3182824e66

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
740

Share

  • Article
  • Figures & Data
  • Info & Disclosures
  • CME Course
Loading

Article Information

vol. 80 no. 7 642-647
DOI: 
https://doi.org/10.1212/WNL.0b013e3182824e66
PubMed: 
23365053

Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received December 23, 2011
  • Accepted October 10, 2012
  • First Published January 30, 2013.

Article Versions

  • Previous version (January 30, 2013 - 13:03).
  • You are viewing the most recent version of this article.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Shazia K. Afridi, MD,
    2. Nicola J. Giffin, MD,
    3. Holger Kaube, MD and
    4. Peter J. Goadsby, MD, PhD
  1. Shazia K. Afridi, MD,
  2. Scientific Advisory Boards:
    1. NONE

    Gifts:
    1. NONE

    Funding for Travel or Speaker Honoraria:
    1. NONE

    Editorial Boards:
    1. NONE

    Patents:
    1. NONE

    Publishing Royalties:
    1. NONE

    Employment, Commercial Entity:
    1. NONE

    Consultancies:
    1. NONE

    Speakers' Bureaus:
    1. NONE

    Other Activities:
    1. NONE

    Clinical Procedures or Imaging Studies:
    1. NONE

    Research Support, Commercial Entities:
    1. NONE

    Research Support, Government Entities:
    1. NONE

    Research Support, Academic Entities:
    1. NONE

    Research Support, Foundations and Societies:
    1. NONE

    Stock/Stock Options/Board of Directors Compensation:
    1. NONE

    License Fee Payments, Technology or Inventions:
    1. NONE

    Royalty Payments, Technology or Inventions:
    1. NONE

    Stock/Stock Options, Research Sponsor:
    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:
    1. NONE

    Legal Proceedings:
    1. NONE

  3. Nicola J. Giffin, MD,
  4. Scientific Advisory Boards:
    1. NONE

    Gifts:
    1. NONE

    Funding for Travel or Speaker Honoraria:
    1. NONE

    Editorial Boards:
    1. NONE

    Patents:
    1. NONE

    Publishing Royalties:
    1. NONE

    Employment, Commercial Entity:
    1. NONE

    Consultancies:
    1. NONE

    Speakers' Bureaus:
    1. NONE

    Other Activities:
    1. NONE

    Clinical Procedures or Imaging Studies:
    1. NONE

    Research Support, Commercial Entities:
    1. NONE

    Research Support, Government Entities:
    1. NONE

    Research Support, Academic Entities:
    1. NONE

    Research Support, Foundations and Societies:
    1. NONE

    Stock/Stock Options/Board of Directors Compensation:
    1. NONE

    License Fee Payments, Technology or Inventions:
    1. NONE

    Royalty Payments, Technology or Inventions:
    1. NONE

    Stock/Stock Options, Research Sponsor:
    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:
    1. NONE

    Legal Proceedings:
    1. NONE

  5. Holger Kaube, MD and
  6. Scientific Advisory Boards:
    1. 1) Merck, Sharp & Dohme, Germany, scientific member 2 years

    Gifts:
    1. NONE

    Funding for Travel or Speaker Honoraria:
    1. NONE

    Editorial Boards:
    1. NONE

    Patents:
    1. NONE

    Publishing Royalties:
    1. NONE

    Employment, Commercial Entity:
    1. 1) Merck, Sharp & Dohme, speaker 2 years, 2) Boehringer-Ingelheim Pharma, speaker 2 years, 3) Pfizer Pharma, speaker, 2 years, 4) Boston Scientific, speaker, 2 years, 5) Medtronic, speaker 2 years, 6) St. Jude Medical, speaker, 2 years, 7) Berlin Chemie, Pharma, speaker, 1 year, 8) MD-Horizonte, speaker, 3 years, 9) Gruenental GmbH, speaker, 1 year

    Consultancies:
    1. NONE

    Speakers' Bureaus:
    1. NONE

    Other Activities:
    1. NONE

    Clinical Procedures or Imaging Studies:
    1. 1) IV infusion of Aspirin for headache patients outpatient and inpatient 5%, 2 years

    Research Support, Commercial Entities:
    1. 1) Boston Scientific, unrestricted educational grant, 1 year, 2) Medtronic, unrestricted educational grant, 2 years, 3) St. Jude Medical, unrestricted educational grant, 1 years

    Research Support, Government Entities:
    1. NONE

    Research Support, Academic Entities:
    1. NONE

    Research Support, Foundations and Societies:
    1. NONE

    Stock/Stock Options/Board of Directors Compensation:
    1. NONE

    License Fee Payments, Technology or Inventions:
    1. NONE

    Royalty Payments, Technology or Inventions:
    1. NONE

    Stock/Stock Options, Research Sponsor:
    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:
    1. NONE

    Legal Proceedings:
    1. NONE

  7. Peter J. Goadsby, MD, PhD
  8. Scientific Advisory Boards:
    1. I have consulted for the following commercial entities, Alder Bio, Allergan, Amgen, ATI, Boehringer-Ingelheim, BMS, Boston Scientific, Colucid, Coherex, DrReddy, Eli-Lilly, Gammacore, GlaxoSmithKline, Impax, J&J, Linde Gases, Lundbeck, MAP Pharmaceuticals, Medtronic, MSD, Neuralieve, Nevrocorp, Pfizer, Zogenix

    Gifts:
    1. NONE

    Funding for Travel or Speaker Honoraria:
    1. Commerical speaker honoraria, Mennarini

    Editorial Boards:
    1. Journal Watch Neurology

    Patents:
    1. NONE

    Publishing Royalties:
    1. Lance JW, Goadsby PJ. Mechanism and Management of Headache. (7th ed.) New York: Elsevier, 2005

    Employment, Commercial Entity:
    1. NONE

    Consultancies:
    1. NONE

    Speakers' Bureaus:
    1. NONE

    Other Activities:
    1. NONE

    Clinical Procedures or Imaging Studies:
    1. NONE

    Research Support, Commercial Entities:
    1. GSK, Gammacore, MSD, MAP, Amgen

    Research Support, Government Entities:
    1. Department of Defence (PR100085P1)

    Research Support, Academic Entities:
    1. NONE

    Research Support, Foundations and Societies:
    1. NONE

    Stock/Stock Options/Board of Directors Compensation:
    1. NONE

    License Fee Payments, Technology or Inventions:
    1. NONE

    Royalty Payments, Technology or Inventions:
    1. NONE

    Stock/Stock Options, Research Sponsor:
    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:
    1. NONE

    Legal Proceedings:
    1. Legal firms handling patent matters

  1. From the Headache Group, Department of Neurology, University of California, San Francisco. S.K.A. is currently affiliated with the Department of Neurology, Guy's Hospital, London, UK. N.J.G. is currently affiliated with the Department of Neurology, Royal United Hospital, Bath, UK. H.K. is currently located in Munich, Germany.
  1. Correspondence to Dr. Goadsby: pgoadsby{at}headache.ucsf.edu
View Full Text

Article usage

Article usage: January 2013 to April 2022

AbstractFullPdfSource
Jan 20139908Highwire
Feb 201317076899Highwire
Mar 20134382338Highwire
Apr 20132882827Highwire
May 20131821226Highwire
Jun 20131171210Highwire
Jul 20131271021Highwire
Aug 2013109611Highwire
Sep 201377914Highwire
Oct 2013661111Highwire
Nov 2013681510Highwire
Dec 201390158Highwire
Jan 201483510Highwire
Feb 2014552014Highwire
Mar 2014881219Highwire
Apr 20145865Highwire
May 201462310Highwire
Jun 20143694Highwire
Jul 20141061411Highwire
Aug 201443103Highwire
Sep 201457109Highwire
Oct 20145557Highwire
Nov 20145298Highwire
Dec 2014451710Highwire
Jan 2015481610Highwire
Feb 201538168Highwire
Mar 20155823Highwire
Apr 20152554Highwire
May 20154732Highwire
Jun 20156233Highwire
Jul 20156685Highwire
Aug 20156432Highwire
Sep 20153963Highwire
Oct 20154832Highwire
Nov 20154503Highwire
Dec 20156244Highwire
Jan 20165544Highwire
Feb 20165812Highwire
Mar 20167978Highwire
Apr 20164724Highwire
May 20164721Highwire
Jun 20166322Highwire
Jul 20168439Highwire
Aug 20166515Highwire
Sep 20165124Highwire
Oct 20167632Highwire
Nov 20167365Highwire
Dec 20165646Highwire
Jan 20176725Highwire
Feb 201763313Highwire
Mar 20176278Highwire
Apr 20175752Highwire
May 20177542Highwire
Jun 20175276Highwire
Jul 20176943Highwire
Aug 20177553Highwire
Sep 20175102Highwire
Oct 201772910Highwire
Nov 20176955Highwire
Dec 20177411Highwire
Jan 20187532Highwire
Feb 20188379Highwire
Mar 20188365Highwire
Apr 201812732Highwire
May 20187347Highwire
Jun 20187655Highwire
Jul 20185511Highwire
Aug 20188241Highwire
Sep 20186365Highwire
Oct 20186831Highwire
Nov 20189344Highwire
Dec 201810211Highwire
Jan 201910865Highwire
Feb 20197445Highwire
Mar 201910659Highwire
Apr 201994911Highwire
May 20198936Highwire
Jun 20194403Highwire
Jul 20198724Highwire
Aug 20198113Highwire
Sep 20198053Highwire
Oct 20199745Highwire
Nov 20198022Highwire
Dec 20195254Highwire
Jan 20209545Highwire
Feb 20205424Highwire
Mar 20205095Highwire
Apr 20206025Highwire
May 20203924Highwire
Jun 20208733Highwire
Jul 20204234Highwire
Aug 20205453Highwire
Sep 20207261Highwire
Oct 20205704Highwire
Nov 20206214Highwire
Dec 20206431Highwire
Jan 20218513Highwire
Feb 20215011Highwire
Mar 202113093Highwire
Apr 20217074Highwire
May 20216722Highwire
Jun 20214700Highwire
Jul 20214213Highwire
Aug 20216852Highwire
Sep 20214713Highwire
Oct 20214803Highwire
Nov 20217134Highwire
Dec 20215902Highwire
Jan 20226022Highwire
Feb 20228913Highwire
Mar 20226522Highwire
Apr 20226033Highwire

Cited By...

  • 86 Citations
  • Google Scholar

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
  • CME Course

More Online

CME Course

Related Articles

  • Diagnostic shifts in ALS?From clinical specter to imaging spectra
  • Biomarkers for PDHow can we approach complexity?
  • Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS
  • Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease
  • Warfarin treatment and thrombolysisHow to persuade procrastinators?
  • tPA and warfarinTime to move forward
  • Neighborhood socioeconomic status and stroke mortalityDisentangling individual and area effects
  • The border-land of epilepsy—Revisited

Topics Discussed

  • Clinical trials Randomized controlled (CONSORT agreement)
  • Migraine
  • Class III

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise